Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.64 |
| ▸ | CA2 | P00918 | 4/20 | 0.64 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | KIF11 | P52732 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11707345 | 0.82 | CA1 (0.67) | CA1CA2CES1KIF11ALDH1A1 | |
| SCHEMBL2135785 | 0.79 | CES1 (0.61) | CA1CA2CES1KIF11ALDH1A1 | |
| SCHEMBL14571959 | 0.79 | CA2 (0.57) | CA1CA2CES1KIF11ALDH1A1 | |
| SCHEMBL1615445 | 0.78 | ALDH1A1 (0.50) | CA1CA2ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL3367354 | 0.78 | CA1 (0.61) | CA1CA2ALDH1A1TDP1PGR | |
| SCHEMBL479173 | 0.78 | KIF11 (0.88) | CA1CA2CES1KIF11ALDH1A1 | |
| SCHEMBL3365049 | 0.78 | CA1 (0.61) | CA1CA2PGRCYP3A4MEN1 | |
| SCHEMBL1645913 | 0.78 | CA1 (1.00) | CA1CA2CES1KIF11PRMT1 | |
| SCHEMBL15549491 | 0.78 | CA1 (0.61) | CA1CA2CES1KIF11ALDH1A1 | |
| SCHEMBL3088460 | 0.78 | CA1 (0.61) | CA1CA2CES1KIF11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382270-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | ATUX ISKAY LLC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250340514-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | ATUX ISKAY LLC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | Maxymune Therapeutics, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12398103-B2 | 3-diarylmethylenes and uses thereof | ATUX ISKAY LLC (US) | 2025-08-26 | — | — | US | disclosed |
| US-20230146127-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | ATUX ISKAY LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230146127-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | ATUX ISKAY LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230146127-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | ATUX ISKAY LLC | 2023-05-11 | — | — | US | disclosed |
| EP-4121031-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | Atux Iskay LLC (US) | 2023-01-25 | — | — | EP | disclosed |
| US-6683201-B2 | FOR THERAPY AND PROPHYLAXIS OF HYPERCHOLESTEROLEMIA, HYPERLIPEMIA, ARTERIOSCLEROSIS, VASCULAR DISEASES, MYCOSES, PARASITE INFECTIONS, GALLSTONES, TUMORS AND/OR HYPERPROLIFERATIVE DISORDERS, DIABETES | HOFFMANN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| EP-1358162-A1 | DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| EP-1311475-A1 | NOVEL AMINOCYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-21 | — | — | EP | disclosed |
| EP-1303503-A2 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-20030004156-A1 | Dihydroindole and tetrahydroquinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-02 | — | — | US | disclosed |
| WO-2002050041-A1 | DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-27 | — | — | WO | disclosed |
| US-20020045777-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | disclosed |
| US-20020038025-A1 | Analine derivatives as OSC inhibitors | F.HOFFMANN-LA ROCHE AG (CH) | 2002-03-28 | — | — | US | disclosed |
| WO-2002014267-A1 | NOVEL AMINOCYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-21 | — | — | WO | disclosed |
| WO-2002006189-A2 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382270-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | MYC, MYCBP, FOXO1 | CA1 4607/4885CA2 4322/4885CES1 4410/4885 |
| US-12398103-B2 | 3-diarylmethylenes and uses thereof | MYC, MYCBP, FOXO1 | CA1 4607/4885CA2 4322/4885CES1 4410/4885 |
| US-20250340514-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | MYC, MYCBP, FOXO1 | CA1 4607/4885CA2 4322/4885CES1 4410/4885 |
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | CA1 4697/4885CA2 3741/4885CES1 820/4885 |
| US-20230146127-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | MYC, MYCBP, FOXO1 | CA1 4607/4885CA2 4322/4885CES1 4410/4885 |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | SLC43A1, SLC7A1, SLC1A5 | CA1 4697/4885CA2 3741/4885CES1 820/4885 |
| US-20030004156-A1 | Dihydroindole and tetrahydroquinoline derivatives | CYP46A1, LSS, CYP51A1 | CA1 2837/4885CA2 2617/4885CES1 72/4885 |
| US-20020038025-A1 | Analine derivatives as OSC inhibitors | LSS, CYP51A1, CYP46A1 | CA1 1870/4885CA2 3023/4885CES1 43/4885 |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | CA1 4697/4885CA2 3741/4885CES1 820/4885 |
| US-20020045777-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | CA1 2475/4885CA2 2022/4885CES1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.